Venous hemangioma

Summary

Venous hemangioma (MONDO:0003083) is a disease and 22 clinical trials. Top therapeutic interventions include enalapril, sirolimus, and alcohol. A subtype of hemangioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 22

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	venous hemangioma
Mondo ID	MONDO:0003083
DOID	DOID:467
NCIT	C4296
SNOMED CT	403968005
UMLS	C0334532
MedGen	90801
Is cancer (heuristic)	no

Also known as: Venous angioma · Venous malformation

Disease family

This is a subtype of hemangioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › cardiovascular organ benign neoplasm › benign blood vessel neoplasm › hemangioma › venous hemangioma

Related subtypes (27): malignant hemangioma, arteriovenous hemangioma/malformation, hemangioma of orbit, intra-abdominal hemangioma, capillary hemangioma, deep hemangioma, skin hemangioma, subglottic hemangioma, breast hemangioma, cavernous hemangioma, glomeruloid hemangioma, hemangioma of lung, acquired hemangioma, central nervous system hemangioma, hobnail hemangioma, synovial angioma, placental hemangioma, hemangioma of subcutaneous tissue, hemangiomas of small intestine, spindle cell hemangioma, infantile hemangioma of rare localization, congenital hemangioma, epithelioid hemangioma, hemangioma of retina, hemangioma of choroid, hemangioma of gingiva, diffuse cavernous hemangioma of the rectum

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 22.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	12
PHASE2	6
PHASE4	2
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01347294	PHASE4	UNKNOWN	Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations
NCT03767660	PHASE4	UNKNOWN	Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation
NCT07285005	PHASE3	NOT_YET_RECRUITING	A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome
NCT04861064	PHASE2	RECRUITING	Weekly Sirolimus Therapy
NCT05983159	PHASE2	RECRUITING	A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
NCT06788314	PHASE2	RECRUITING	A Study of Enalapril in Treatment of Venous Malformations
NCT07477548	PHASE2	NOT_YET_RECRUITING	A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies
NCT00462462	PHASE2	COMPLETED	Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.
NCT04258046	PHASE2	COMPLETED	Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation
NCT04409145	PHASE1/PHASE2	TERMINATED	First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations
NCT06642051	Not specified	ACTIVE_NOT_RECRUITING	Safety of the Sonablate HIFU System for the Ablation of Incompetent Veins of the Periphery
NCT06994260	Not specified	NOT_YET_RECRUITING	Diagnostic Imaging of Vascular Malformations Using MSOT and ULM
NCT07066527	Not specified	RECRUITING	Efficacy and Safety Analysis of Polylauric Alcohol More Stable Foam Versus Ordinary Foam in the Treatment of Head and Neck Venous Malformations
NCT07404670	Not specified	NOT_YET_RECRUITING	Microwave Ablation for Treatment of Vascular Malformations: Efficacy and Safety
NCT00577213	Not specified	COMPLETED	Diagnosis of Hemangiomas and Vascular Malformations
NCT00866827	Not specified	COMPLETED	Airway Vascular Lesions
NCT04486599	Not specified	COMPLETED	Electromagnetic Navigation During Ultrasound Guided Foam Sclerotherapy for Venous Malformations
NCT04637997	Not specified	COMPLETED	Influence of Flat-knitted Compression Stockings Class I and II on Venous Malformations
NCT04836884	Not specified	COMPLETED	Vascular Anomaly Pathology and Genomics Biopsy Study
NCT04930952	Not specified	COMPLETED	Complications of Ethanol-amine Oleate Intralesional Sclerotherapy
NCT05563831	Not specified	COMPLETED	National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
NCT05586919	Not specified	COMPLETED	Treatment of Venous Malformation

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ENALAPRIL	4	3
SIROLIMUS	4	2
ALCOHOL	4	1
ALPELISIB	4	1
BLEOMYCIN	4	1
POLIDOCANOL	4	1
SODIUM TETRADECYL SULFATE	4	1
MIRDAMETINIB	2	1
CHEMBL5433950	0	1
CHEMBL1231723	0	1